Middle East News Watch
SEE OTHER BRANDS

The latest news from the Middle East

Middle East News Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Watch.

Press releases published on June 9, 2025

Aventis Energy Announces Exploration Plans at its Corvo Uranium Project

Aventis Energy Announces Exploration Plans at its Corvo Uranium Project

VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to provide a summary of 2025 exploration programs planned on its Corvo Uranium Project (the “ …

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC

Event to Discuss the Changing Landscape of HNSCC in context with the Merck KN-689 study and the Rapidly Increasing Incidences of HPV16-positive HNSCC in the United States and Europe Webinar to be held Tuesday, June 17, 2025, 12:00 PM ET PRINCETON, N.J., …

Bitcoin Solaris Presale Heats Up in Phase 7 as Token Launch Nears with 233% ROI Forecast

Bitcoin Solaris Presale Heats Up in Phase 7 as Token Launch Nears with 233% ROI Forecast

TALLINN, Estonia, June 09, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain project, has officially entered Phase 7 of its presale, offering early participants a strategic entry point ahead of its upcoming exchange launch. …

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

D-PLEX100 successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions. The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in …

Alarum Technologies Updates Second Quarter 2025 Revenue and Adjusted EBITDA Outlook

Alarum Technologies Updates Second Quarter 2025 Revenue and Adjusted EBITDA Outlook

TEL AVIV, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced an update to its revenue and Adjusted EBITDA outlook for the …

Oddity Finance LLC Announces Proposed $350 Million Offering of 0% Exchangeable Senior Notes Due 2030

Oddity Finance LLC Announces Proposed $350 Million Offering of 0% Exchangeable Senior Notes Due 2030

As of March 31, 2025, ODDITY had $257 million in cash, and an undrawn $200 million credit line Capital raise gives ODDITY additional firepower to play offense and pursue future opportunities in a volatile world A portion of the proceeds will be used to …

REE Announces Cost Reduction Measures to Sustain Long-Term Growth

REE Announces Cost Reduction Measures to Sustain Long-Term Growth

Initiated cost reduction measures targeting a 55% decrease in operating costs to a projected average of approximately $2.7 million per month by year-end related to pause in production and an approximately 50% reduction-in-force The company aims to extend …

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that the first patient has been dosed in its Phase 3 TERZO …

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Announces Return of $375 Million in Excess Capital to Stockholders

LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service